Cancer

Fountain Life continues mission to transform healthcare with new center openings

The world's leading science-backed longevity membership is opening its newest wellness center location in Houston, Texas HOUSTON, March 25, 2025…

9 months ago

CommunityRewards™ Will Co-Host 305 Pink Pack Night at Miami Heat vs. Atlanta Hawks Game This Thursday, March 27, 2025 to Close Out $50,000 Fundraiser Project for Women in Miami Battling Cancer

MIAMI, March 25, 2025 /PRNewswire/ -- CommunityRewards™ is partnering with 305 Pink Pack to close out Women's History Month on Thursday,…

9 months ago

PathAI Showcases AI-Powered Pathology Innovations at the United States and Canadian Academy of Pathology (USCAP) 114th Annual Meeting

Company to present key research advancing digital pathology and host a networking event, H&E by the Sea, on March 25th…

9 months ago

Oncotelic Therapeutics Announces Successful Completion of Phase 1 Trial of OT-101 and IL-2, Highlights Findings at SWCR 2025 Conference

AGOURA HILLS, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”),…

9 months ago

Marius Pharmaceuticals Strengthens IP Portfolio with New KYZATREX® (testosterone undecanoate) CIII Capsules Formulation Patent

RALEIGH, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone…

9 months ago

Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock

WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today…

9 months ago

Syncromune Appoints Zhihong Li, Ph.D., as Chief Regulatory Affairs Officer to Lead Global Regulatory Strategy for Novel Oncology Immunotherapies

FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, March 25, 2025 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company developing…

9 months ago

Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected…

9 months ago

Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer

–  Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two…

9 months ago

Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease

Ernexa Therapeutics embarks on new strategic direction, shifting the company’s focus from delivering a cell therapy platform to prioritizing product…

9 months ago